Molecular MRI of intracranial thrombus in a rat ischemic stroke model

Stroke

Volumn 41, Issue 6, 2010, Pages 1271-1277

  Uppal, Ritika ^a   Ay, Ilknur ^a   Dai, Guangping ^a   Kim, Young Ro ^a   Sorensen, A Gregory ^a   Caravan, Peter ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Fibrin; Gadolinium; Ischemic stroke; Molecular imaging; Thrombus

Indexed keywords

EP-2104R; FIBRIN; GADOLINIUM PENTETATE MEGLUMINE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BRAIN ISCHEMIA; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RAT; THREE DIMENSIONAL IMAGING; THROMBUS; WISTAR RAT;

ANIMALS; BRAIN ISCHEMIA; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; GADOLINIUM; INTRACRANIAL THROMBOSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; PEPTIDES; RATS; RATS, WISTAR; STROKE; THROMBOLYTIC THERAPY;

EID: 77953160474     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.575662     Document Type: Article

References (33)

1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008; 371:1612-1623.
2. Leys D, Pruvo JP, Godefroy O, Rondepierre P, Leclerc X. Prevalence and significance of hyperdense middle cerebral artery in acute stroke. Stroke. 1992;23:317-324.
3. Tomsick TA, Brott TG, Olinger CP, Barsan W, Spilker J, Eberle R, Adams H. Hyperdense middle cerebral artery: incidence and quantitative significance. Neuroradiology. 1989;31:312-315.
4. Goldmakher GV, Camargo EC, Furie KL, Singhal AB, Roccatagliata L, Halpern EF, Chou MJ, Biagini T, Smith WS, Harris GJ, Dillon WP, Gonzalez RG, Koroshetz WJ, Lev MH. Hyperdense basilar artery sign on unenhanced CT predicts thrombus and outcome in acute posterior circulation stroke. Stroke. 2009;40:134-139.
5. Krings T, Noelchen D, Mull M, Willmes K, Meister IG, Reinacher P, Toepper R, Thron AK. The hyperdense posterior cerebral artery sign: a computed tomography marker of acute ischemia in the posterior cerebral artery territory. Stroke. 2006;37:399-403.
6. Leary MC, Kidwell CS, Villablanca JP, Starkman S, Jahan R, Duckwiler GR, Gobin YP, Sykes S, Gough KJ, Ferguson K, Llanes JN, Masamed R, Tremwel M, Ovbiagele B, Vespa PM, Vinuela F, Saver JL. Validation of computed tomographic middle cerebral artery 'dot' sign: an angiographic correlation study. Stroke. 2003;34:2636-2640.
7. Manelfe C, Larrue V, von Kummer R, Bozzao L, Ringleb P, Bastianello S, Iweins F, Lesaffre E. Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator. Stroke. 1999;30:769-772.
8. Mattle HP, Arnold M, Georgiadis D, Baumann C, Nedeltchev K, Ben-ninger D, Remonda L, von Budingen C, Diana A, Pangalu A, Schroth G, Baumgartner RW. Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. Stroke. 2008;39:379-383.
9. Qureshi AI, Ezzeddine MA, Nasar A, Suri MF, Kirmani JF, Janjua N, Divani AA. Is IV tissue plasminogen activator beneficial in patients with hyperdense artery sign? Neurology. 2006;66:1171-1174.
10. Overoye-Chan K, Koerner S, Looby RJ, Kolodziej AF, Zech SG, Deng Q, Chasse JM, McMurry TJ, Caravan P. EP-2104R: a fibrin-specific gadolinium-based MRI contrast agent for detection of thrombus. J Am Chem Soc. 2008;130:6025-6039.
11. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM. Novel MRI contrast agent for molecular imaging of fibrin implications for detecting vulnerable plaques. Circulation. 2001;104:1280-1285.
12. von zur Muhlen C, von Elverfeldt D, Moeller JA, Choudhury RP, Paul D, Hagemeyer CE, Olschewski M, Becker A, Neudorfer I, Bassler N, Schwarz M, Bode C, Peter K. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation. 2008;118:258-267.
13. Spuentrup E, Botnar RM, Wiethoff AJ, Ibrahim T, Kelle S, Katoh M, Oezgun M, Nagel E, Vymazal J, Graham PB, Gunther RW, Maintz D. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol. 2008;18:1995-2005.
14. Vymazal J, Spuentrup E, Cardenas-Molina G, Wiethoff AJ, Hartmann MG, Caravan P, Parsons EC Jr. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase ii clinical study of feasibility. Invest Radiol. 2009;44:697-704.
15. Stracke CP, Katoh M, Wiethoff AJ, Parsons EC, Spangenberg P, Spuntrup E. Molecular MRI of cerebral venous sinus thrombosis using a new fibrin-specific MR contrast agent. Stroke. 2007;38:1476-1481.
16. Spuentrup E, Katoh M, Buecker A, Fausten B, Wiethoff AJ, Wildberger JE, Haage P, Edward CP, Botnar RM, Graham PB, Vettelsehoss M, Gunther RW. Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent. Invest Radiol. 2007;42:586-595. (Pubitemid 47051836)
17. Spuentrup E, Katoh M, Wiethoff AJ, Parsons EC Jr, Botnar RM, Mahnken AH, Gunther RW, Buecker A. Molecular magnetic resonance imaging of pulmonary emboli with a fibrin-specific contrast agent. Am J Respir Crit Care Med. 2005;172:494-500.
18. Spuentrup E, Buecker A, Katoh M, Wiethoff AJ, Parsons EC Jr, Botnar RM, Weisskoff RM, Graham PB, Manning WJ, Gunther RW. Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation. 2005;111: 1377-1382. (Pubitemid 40396803)
19. Spuentrup E, Fausten B, Kinzel S, Wiethoff AJ, Botnar RM, Graham PB, Haller S, Katoh M, Parsons EC Jr, Manning WJ, Busch T, Gunther RW, Buecker A. Molecular magnetic resonance imaging of atrial clots in a swine model. Circulation. 2005;112:396-399.
20. Sirol M, Fuster V, Badimon JJ, Fallon JT, Moreno PR, Toussaint JF, Fayad ZA. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation. 2005;112: 1594-1600. (Pubitemid 41324521)
21. Botnar RM, Buecker A, Wiethoff AJ, Parsons EC Jr, Katoh M, Katsimaglis G, Weisskoff RM, Lauffer RB, Graham PB, Gunther RW, Manning WJ, Spuentrup E. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation. 2004;110:1463-1466.
22. Spuentrup E, Katoh M, Wiethoff AJ, Buecker A, Botnar RM, Parsons EC, Guenther RW. Molecular coronary MR imaging of human thrombi using (Pubitemid 350155124)
23. Katoh M, Haage P, Wiethoff AJ, Gunther RW, Bucker A, Tacke J, Spuentrup E. Molecular magnetic resonance imaging of deep vein thrombosis using a fibrin-targeted contrast agent: a feasibility study. Invest Radiol. 2009;44:146-150 Jan 15 [Epub ahead of print].
24. Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing JR. A rat model of focal embolic cerebral ischemia. Brain Res. 1997;766:83-92. (Pubitemid 27431437)
25. Caravan P, Farrar CT, Frullano L, Uppal R. Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents. Contrast Media Mol Imaging. 2009;4:89-100.
26. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724.
27. Moody AR, Murphy RE, Morgan PS, Martel AL, Delay GS, Allder S, MacSweeney ST, Tennant WG, Gladman J, Lowe J, Hunt BJ. Characterization of complicated carotid plaque with magnetic resonance direct thrombus imaging in patients with cerebral ischemia. Circulation. 2003; 107:3047-3052.
28. Kelly J, Rudd A, Lewis RR, Coshall C, Moody A, Hunt BJ. Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. Stroke. 2004;35: 2320-2325.
29. Hatton MW, Ross B, Timleck M, Southward SM, Richardson M. Turnover and fate of fibrinogen and platelets at the rabbit aorta wall immediately after a balloon de-endothelializing injury in vivo. Thromb Haemost. 2006;96:60-67.
30. Marder VJ, Chute DJ, Starkman S, Abolian AM, Kidwell C, Liebeskind D, Ovbiagele B, Vinuela F, Duckwiler G, Jahan R, Vespa PM, Selco S, Rajajee V, Kim D, Sanossian N, Saver JL. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke. 2006;37:2086-2093. (Pubitemid 44309909)
31. Bini A, Fenoglio J Jr, Sobel J, Owen J, Fejgl M, Kaplan KL. Immuno-chemical characterization of fibrinogen, fibrin I, and fibrin II in human thrombi and atherosclerotic lesions. Blood. 1987;69:1038-1045.
32. Francis CW, Markham RE Jr, Marder VJ. Demonstration of in situ fibrin degradation in pathologic thrombi. Blood. 1984;63:1216-1224.
33. Rosebrough SF, Grossman ZD, McAfee JG, Kudryk BJ, Subramanian G, Ritter-Hrncirik CA, Witanowski LS, Tillapaugh-Fay G, Urrutia E. Aged venous thrombi: radioimmunoimaging with fibrin-specific monoclonal antibody. Radiology. 1987;162:575-577.